> ## Content Index > Fetch the complete content index at: https://www.whiteroseintelligence.com/llms.txt > Use this file to discover other available public pages before exploring further. # National Advisory Committee on Immunization - URL: https://www.whiteroseintelligence.com/national-advisory-committee-on-immunization/ - Published: 1999-01-02T20:44:00.000Z - Updated: 2025-11-14T17:52:53.000Z - Author: Liam Sturgess - Tags: Profiles, #docs, #organization The **National Advisory Committee on Immunization (NACI)** is a Canadian advisory body operating within the [Public Health Agency of Canada](https://www.whiteroseintelligence.com/Public-Health-Agency-of-Canada) (PHAC).[\[1\]](#fn1) It is tasked with “providing guidance on the use of vaccines currently or newly approved for use in Canada to the [Government of Canada](https://www.whiteroseintelligence.com/Government-of-Canada).”[\[2\]](#fn2) ## History NACI was formed in 1964.[\[2:1\]](#fn2) ### COVID-19 On April 23, 2021, NACI recommended the [AstraZeneca-Oxford COVID-19 vaccine](https://www.whiteroseintelligence.com/AstraZeneca-COVID-19-vaccine) be offered to “all Canadians over the age of 30, but only when the benefits outweigh the risks of rare, serious post-vaccine blood clots.”[\[3\]](#fn3) On June 29, 2022, NACI issued guidance recommending “booster doses” of [COVID-19 vaccines](https://www.whiteroseintelligence.com/COVID-19-vaccine) for all “Canadians at increased risk of serious illness from COVID-19,” regardless of how many doses they had previously received.[\[4\]](#fn4) On March 3, 2023, NACI called for “high-risk individuals” to receive another booster dose in the spring.[\[5\]](#fn5)[\[6\]](#fn6) On July 11, 2023, NACI once again strongly recommended that all individuals over the age of 5 receive a "primary series" of COVID-19 vaccines, with a less emphatic recommendation for those aged 6 months to five years. They also recommended an additional dose of "the new formulation of COVID-19 vaccine for individuals in the authorized age group if it has been at least 6 months from the previous COVID-19 vaccine dose or known SARS-CoV-2 infection."[\[7\]](#fn7)[\[8\]](#fn8) ## Personnel | Name | Position | Notes | | -------------------------------------------------------------------------- | ------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | | Shelley Deeks | Chair[\[9\]](#fn9) | Nova Scotia Department of Health and Wellness | | Robyn Harrison | Vice-chair | Grey Nuns Community Hospital, University of Alberta Hospital | | Melissa Andrew | Member | Dalhousie University | | Julie Bettinger | Member | University of British Columbia | | Nicholas Brousseau | Member | Laval University | | Hélène Decaluwe | Member | Research Centre of the Sainte-Justine University Hospital | | Philippe De Wals | Member | Laval University Department of Social and Preventive Medicine | | [Eve Dubé](https://www.whiteroseintelligence.com/Eve-Dube) | Member | [Institut national de santé publique du Québec](https://www.whiteroseintelligence.com/Institut-national-de-sant%C3%A9-publique-du-Qu%C3%A9bec) | | Vinita Dubey | Member | [Toronto Public Health](https://www.whiteroseintelligence.com/Toronto-Public-Health) | | Kyla Hildebrand | Member | University of British Columbia | | Kristin Klein | Member | [Alberta Health Services](https://www.whiteroseintelligence.com/Alberta-Health-Services) | | Miranda O'Driscoll | Member | Newfoundland and Labrador Department of Health and Community Services | | Jesse Papenburg | Member | McGill University Health Centre (MUHC) | | Anne Pham-Huy | Member | Children's Hospital of Eastern Ontario (CHEO) | | [Beate Sander](https://www.whiteroseintelligence.com/Beate-Sander) | Member | Toronto General Hospital | | Sarah Wilson | Member | [Public Health Ontario](https://www.whiteroseintelligence.com/Public-Health-Ontario) | | Natalie Dayneka | Member (former)[\[10\]](#fn10) | Children's Hospital of Eastern Ontario (CHEO) | | Soren Gantt | Member (former) | University of Montreal | | [Coleman Rotstein](https://www.whiteroseintelligence.com/Coleman-Rotstein) | Member (former) | University of Toronto | | [Althea House](https://www.whiteroseintelligence.com/Althea-House) | Member (former) | [Public Health Agency of Canada](https://www.whiteroseintelligence.com/Public-Health-Agency-of-Canada) | | Matthew Tunis | Executive secretary | \- | | Jeannette Comeau | Liaison representative | [Association of Medical Microbiology and Infectious Disease Canada](https://www.whiteroseintelligence.com/Association-of-Medical-Microbiology-and-Infectious-Disease-Canada) (AMMI) | | Sarah Buchan | Liaison representative | Canadian Association for Immunization Research and Evaluation (CAIRE) | | [Monika Naus](https://www.whiteroseintelligence.com/Monika-Naus) | Liaison representative | Canadian Immunization Committee (CIC) | | Lea Bill | Liaison representative | Canadian Indigenous Nurses Association | | Lucie Marisa Bucci | Liaison representative | [Canadian Public Health Association](https://www.whiteroseintelligence.com/Canadian-Public-Health-Association) (CPHA) | | Amanda Ung | Liaison representative | Canadian Pharmacists Association | | Dorothy Moore | Liaison representative | [Canadian Paediatric Society](https://www.whiteroseintelligence.com/Canadian-Paediatric-Society) | | Martin Lavoie | Liaison representative | [Council of Chief Medical Officers of Health](https://www.whiteroseintelligence.com/Council-of-Chief-Medical-Officers-of-Health) | | Jessica MacNeil | Liaison representative | [Centers for Disease Control and Prevention](https://www.whiteroseintelligence.com/Centers-for-Disease-Control-and-Prevention) (CDC) | | Melanie Osmack | Liaison representative | Indigenous Physicians Association of Canada | | Eliana Castillo | Liaison representative | Society of Obstetrics and Gyneacologists | | Vacant | Liaison representative | Canadian Nurses Association | | Jen Potter | Liaison representative | College of Family Physicians of Canada | | Julie Emili | Liaison representative (former) | College of Family Physicians of Canada | | Co Pham | Ex-officio | [Biologics and Genetic Therapies Directorate](https://www.whiteroseintelligence.com/Biologic-and-Radiopharmaceutical-Drugs-Directorate) | | Robert Pless | Ex-officio (former) | [Biologics and Genetic Therapies Directorate](https://www.whiteroseintelligence.com/Biologic-and-Radiopharmaceutical-Drugs-Directorate) | | Vincent Beswick-Escanlar | Ex-officio | Directorate of Force Health Protection | | Ming Su | Ex-officio | [Public Health Agency of Canada](https://www.whiteroseintelligence.com/Public-Health-Agency-of-Canada) | | Erin Henry | Ex-officio | Centre for Immunization Readiness (CIR) | | Patrick Fandja | Ex-officio | [Marketed Health Products Directorate](https://www.whiteroseintelligence.com/Marketed-Health-Products-Directorate) | | Deborah Danoff | Ex-officio (former) | [Marketed Health Products Directorate](https://www.whiteroseintelligence.com/Marketed-Health-Products-Directorate) | | Michael Routledge | Ex-officio | National Microbiology Laboratory | | Susanna Ogunnaike-Cooke | Ex-officio | [Public Health Agency of Canada](https://www.whiteroseintelligence.com/Public-Health-Agency-of-Canada) | | Tom Wong | Ex-officio | First Nations and Inuit Health Branch | | Mireille Lacroix | Ex-officio | Public Health Ethics Consultative Group (PHECG) | ## Publications NACI's official statements about [COVID-19 vaccines](https://www.whiteroseintelligence.com/COVID-19-vaccine) are as follows:[\[11\]](#fn11) 1. December 12, 2020: [Recommendations on the use of COVID-19 vaccine(s)](http://archive.today/2023.06.26-200216/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/december-12-2020.html) 2. December 23, 2020: [Recommendations on the use of COVID-19 vaccines](https://web.archive.org/web/20240119155102/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/december-23-2020.html) 3. January 12, 2021: [Recommendations on the use of COVID-19 vaccines](https://web.archive.org/web/20210304163147/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/january-12-2021.html) 4. March 1, 2021: [Recommendations on the use of COVID-19 vaccines](https://web.archive.org/web/20210318082956/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/march-1-2021.html) 5. March 3, 2021: [NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada](http://archive.today/2021.03.05-002414/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html) 6. March 16, 2021: [Recommendations on the use of COVID-19 vaccines](http://archive.today/2021.05.03-201652/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/march-16-2021.html) - [Summary of updated NACI vaccine statement of March 16, 2021](https://web.archive.org/web/20210316125442/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/summary-updated-statement-16-march-2021.html) 7. March 29, 2021: [NACI rapid response: Recommended use of AstraZeneca COVID-19 vaccine in younger adults](http://archive.today/2021.03.30-031505/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-recommended-use-astrazeneca-covid-19-vaccine-younger-adults.html) 8. April 7, 2021: [Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada in the context of limited vaccine supply](https://web.archive.org/web/20210410044652/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html) - [Summary of extended dose interval statement of April 7, 2021](https://web.archive.org/web/20210415103233/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/covid-19-summary-extended-dose-interval.html) 9. April 23, 2021: [Recommendations on the use of COVID-19 vaccines](https://web.archive.org/web/20240306234934/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/april-23-2021.html) - [Summary of updated NACI vaccine statement of April 23, 2021](http://archive.today/2021.04.24-111532/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/summary-updated-statement-april-23-2021.html) 10. May 3, 2021: [Recommendations on the use of COVID-19 vaccines](https://web.archive.org/web/20210530042743/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/may-3-2021.html) - [Summary of updated vaccine statement of May 3, 2021](http://archive.today/2021.05.03-210457/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/summary-updated-statement-may-3-2021.html) 11. May 18, 2021: [Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine in adolescents 12 to 18 years of age](http://archive.today/2024.03.07-000410/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendation-use-pfizer-biontech-covid-19-vaccine-adolescents.html) - [Summary of National Advisory Committee on Immunization statement of May 18, 2021](http://archive.today/2024.03.07-000406/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/summary-updated-statement-may-18-2021.html) 12. May 28, 2021: [Recommendations on the use of COVID-19 vaccines](https://web.archive.org/web/20210617193932/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/may-28-2021.html) - [Summary of National Advisory Committee on Immunization statement of May 28, 2021](https://web.archive.org/web/20210528153048/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/summary-updated-statement-may-28-2021.html) 13. June 1, 2021: [Interchangeability of authorized COVID-19 vaccines](http://archive.today/2021.06.15-180626/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/rapid-response-interchangeability.html) - [Summary of NACI rapid response of June 1, 2021](http://archive.today/2021.06.07-202539/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/rapid-response-interchangeability/summary.html) 14. June 17, 2021: [Recommendations on the use of COVID-19 vaccines](https://web.archive.org/web/20210708040929/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/june-17-2021.html) - [Summary of National Advisory Committee on Immunization statement of June 17, 2021](http://archive.today/2021.06.19-165848/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/summary-statement-june-17-2021.html) 15. July 2, 2021: [Recommendations on the use of COVID-19 vaccines](https://web.archive.org/web/20210729112757/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/july-2-2021.html) - [Summary of National Advisory Committee on Immunization (NACI) updates of July 2, 2021](https://web.archive.org/web/20210707150726/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/summary-updates-july-2-2021.html) 16. July 22, 2021: [Recommendations on the use of COVID-19 vaccines](https://web.archive.org/web/20210930220623/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/july-22-2021.html) - [Summary of National Advisory Committee on Immunization (NACI) updates of July 22, 2021](https://web.archive.org/web/20210722193309/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/summary-updates-july-22-2021.html) 17. August 27, 2021: [Recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age](http://archive.today/2021.10.01-192005/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/mrna-adolescents.html) - [Summary of National Advisory Committee on Immunization (NACI) statement: Recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age](http://archive.today/2021.11.26-214218/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/mrna-adolescents/summary.html) 18. September 10, 2021: [National Advisory Committee on Immunization (NACI) rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary series](http://archive.today/2021.09.23-211147/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/statement-september-10-2021-additional-dose-covid-19-vaccine-immunocompromised-following-1-2-dose-series.html) - [Summary of National Advisory Committee on Immunization (NACI) rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following a 1- or 2-dose primary series](https://web.archive.org/web/20210910153522/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/summary-september-10-2021-additional-dose-covid-19-vaccine-immunocompromised-following-1-2-dose-series.html) 19. September 28, 2021: [Recommendations on the use of COVID-19 vaccines](https://web.archive.org/web/20211028094322/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/september-28-2021.html) - [Summary of National Advisory Committee on Immunization (NACI) statement: Recommendations on the use of COVID-19 vaccines](https://web.archive.org/web/20210928193435/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/summary-updates-september-28-2021.html) 20. September 28, 2021: [NACI rapid response: Booster dose in long-term care residents and seniors living in other congregate settings](https://web.archive.org/web/20210928213538/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/statement-september-28-2021-booster-dose-long-term-care-residents-seniors-living-other-congregate-settings.html) - [Summary of National Advisory Committee on Immunization (NACI) rapid response: Booster dose of COVID-19 vaccine in long-term care residents and seniors living in other congregate settings](http://archive.today/2024.03.07-003710/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/summary-september-28-2021-booster-dose-long-term-care-residents-seniors-living-other-congregate-settings.html) 21. October 22, 2021: [Recommendations on the use of COVID-19 vaccines](https://web.archive.org/web/20211022145112/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/summary-october-22-2021.html) - [Summary of National Advisory Committee on Immunization (NACI) statement: Recommendations on the use of COVID-19 vaccines](https://web.archive.org/web/20211022145112/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/summary-october-22-2021.html) 22. December 12, 2020-October 22, 2021: [Table of updates: Recommendations on the use of COVID-19 vaccines](https://web.archive.org/web/20240306234719/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/table-updates.html) 23. October 29, 2021: [Interim guidance on booster COVID-19 vaccine doses in Canada](http://archive.today/2022.08.21-153316/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/statement-guidance-booster-doses.html) - [Summary of National Advisory Committee on Immunization statement: Interim guidance on booster COVID-19 vaccine doses in Canada](https://web.archive.org/web/20211105152723/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/statement-guidance-booster-doses/summary.html) 24. November 19, 2021: [Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5 to 11 years of age](https://web.archive.org/web/20211124094843/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/pfizer-biontech-10-mcg-children-5-11-years-age.html) - [Summary of National Advisory Committee on Immunization (NACI) statement: Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5 to 11 years of age](http://archive.today/2021.11.27-150537/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/pfizer-biontech-10-mcg-children-5-11-years-age/summary.html) 25. December 3, 2021: [NACI rapid response: Updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines](https://web.archive.org/web/20211213082105/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-recommendation-use-covid-19-vaccines-individuals-aged-12-years-older-myocarditis-pericarditis-reported-following-mrna-vaccines.html) - [Summary of NACI rapid response of December 3, 2021: Updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccination](https://web.archive.org/web/20211214050708/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-recommendation-use-covid-19-vaccines-individuals-aged-12-years-older-myocarditis-pericarditis-reported-following-mrna-vaccines/summary.html) 26. December 3, 2021: [NACI updated guidance on booster COVID-19 vaccine doses in Canada](https://web.archive.org/web/20211215203826/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-booster-covid-19-vaccine-doses.html) - [Summary of NACI updated guidance of December 3, 2021: Booster COVID-19 vaccine doses in Canada](https://web.archive.org/web/20211210000314/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-booster-covid-19-vaccine-doses/summary.html) 27. January 25, 2022: [NACI updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age](https://web.archive.org/web/20220128105337/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/updated-recommendations-use-covid-19-vaccines-children-5-11-years-age.html) - [Amendment to January 25, 2022: NACI updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age](https://web.archive.org/web/20220311004124/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/updated-recommendations-use-covid-19-vaccines-children-5-11-years-age/amendment-january-25-2022.html) - [Summary of NACI statement of January 25, 2022: Updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age](https://web.archive.org/web/20220131071949/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/updated-recommendations-use-covid-19-vaccines-children-5-11-years-age/summary.html) 28. January 28, 2022: [NACI rapid response: Guidance on the use of booster COVID-19 vaccine doses in adolescents 12 to 17 years of age](https://web.archive.org/web/20220210112947/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-guidance-use-booster-covid-19-vaccine-doses-adolescents-12-17-years-age.html) - [Summary of the NACI rapid response of January 28, 2022: Guidance on the use of booster COVID-19 vaccine doses in adolescents 12 to 17 years of age](https://web.archive.org/web/20220210113036/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-guidance-use-booster-covid-19-vaccine-doses-adolescents-12-17-years-age/summary.html) 29. February 4, 2022: [NACI rapid response: Updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2](http://archive.today/2022.04.22-032910/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-guidance-covid-19-vaccination-timing-individuals-previously-infected-sars-cov-2.html) - [Summary of NACI rapid response of February 4, 2022: Updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2](https://web.archive.org/web/20220217224926/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-guidance-covid-19-vaccination-timing-individuals-previously-infected-sars-cov-2/summary.html) 30. February 17, 2022: [Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine](https://web.archive.org/web/20220226191214/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-novavax-nuvaxovid-covid-19-vaccine.html) - [Summary of NACI statement of February 17, 2022: Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine](https://web.archive.org/web/20220227171434/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-novavax-nuvaxovid-covid-19-vaccine/summary-february-17-2022.html) 31. March 11, 2022: [Recommendations on the use of Medicago COVID-19 vaccine (Covifenz)](https://web.archive.org/web/20220324025241/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-medicago-covid-19-vaccine.html) - [Summary of NACI statement of March 11, 2022: Recommendations on the use of Medicago COVID-19 vaccine (Covifenz)](https://web.archive.org/web/20220324025253/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-medicago-covid-19-vaccine/summary-march-11-2022.html) 32. March 17, 2022: [Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 to 11 years of age](https://web.archive.org/web/20220324025137/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-moderna-spikevax-covid-19-vaccine-children-6-11-years-age.html) - [Summary of NACI statement of March 17, 2022: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 to 11 years of age](https://web.archive.org/web/20220324025155/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-moderna-spikevax-covid-19-vaccine-children-6-11-years-age/summary-march-17-2022.html) 33. April 5, 2022: [Initial guidance on a second booster dose of COVID-19 vaccines in Canada](http://archive.today/2022.06.15-153241/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-second-booster-dose-covid-19-vaccines.html) - [Summary of NACI statement of April 5, 2022: Initial guidance on a second booster dose of COVID-19 vaccines in Canada](https://web.archive.org/web/20220429004812/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-second-booster-dose-covid-19-vaccines/summary-april-5-2022.html) 34. April 12, 2022: [Updated guidance on a first booster dose of COVID-19 vaccines in Canada](https://web.archive.org/web/20220429001241/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-first-booster-dose-covid-19-vaccines.html) - [Summary of NACI statement of April 12, 2022: Updated guidance on a first booster dose of COVID-19 vaccines in Canada](https://web.archive.org/web/20220429001315/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-first-booster-dose-covid-19-vaccines/summary-april-12-2022.html) 35. June 29, 2022: [Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada](https://web.archive.org/web/20220729124104/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-planning-fall-2022-covid-19-vaccine-booster.html) - [Summary of NACI statement of June 29, 2022: Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada](https://web.archive.org/web/20220802233251/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-planning-fall-2022-covid-19-vaccine-booster/summary-june-29-2022.html) 36. July 14, 2022: [Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age](https://web.archive.org/web/20220728161303/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-moderna-spikevax-covid-19-vaccine-children-6-months-5-years.html) - [Summary of NACI statement of July 14, 2022: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age](http://archive.today/2022.09.13-074334/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-moderna-spikevax-covid-19-vaccine-children-6-months-5-years/summary-july-14-2022.html) 37. August 19, 2022: [Recommendations on the use of a first booster dose of Pfizer-BioNTech Comirnaty COVID-19 vaccine in children 5 to 11 years of age](https://web.archive.org/web/20220905234855/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-first-booster-dose-pfizer-biontech-comirnaty-covid-19-vaccine-children-5-11-years.html) - [Summary of NACI statement of August 19, 2022: Recommendations on the use of a first booster dose of Pfizer-BioNTech Comirnaty COVID-19 vaccine in children 5 to 11 years of age](https://web.archive.org/web/20220928012533/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-first-booster-dose-pfizer-biontech-comirnaty-covid-19-vaccine-children-5-11-years/summary-august-19-2022.html) 38. September 1, 2022: [Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines](https://web.archive.org/web/20220928012952/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-bivalent-omicron-containing-mrna-covid-19-vaccines.html) - [Summary of NACI statement of September 1, 2022: Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines](https://web.archive.org/web/20220920022137/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-bivalent-omicron-containing-mrna-covid-19-vaccines/summary-september-1-2022.html) 39. September 9, 2022: [Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding](https://web.archive.org/web/20221122182756/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-covid-19-vaccines-individuals-pregnant-breastfeeding.html) - [Summary of NACI statement: Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding](https://web.archive.org/web/20221122182730/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-covid-19-vaccines-individuals-pregnant-breastfeeding/summary-september-9-2022.html) 40. October 7, 2022: [Updated guidance on COVID-19 vaccine booster doses in Canada](https://web.archive.org/web/20221025201931/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-covid-19-vaccine-booster-doses.html) - [Summary of NACI statement of October 7, 2022: Updated guidance on COVID-19 vaccine booster doses in Canada](https://web.archive.org/web/20221110122037/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-covid-19-vaccine-booster-doses/summary-october-7-2022.html) 41. October 21, 2022: [Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age](https://web.archive.org/web/20221122182717/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-pfizer-biontech-comirnaty-3-mcg-covid-19-vaccine-children-6-months-4-years.html) - [Summary of NACI statement of October 21, 2022: Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age](https://web.archive.org/web/20221122182722/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-pfizer-biontech-comirnaty-3-mcg-covid-19-vaccine-children-6-months-4-years/summary-october-21-2022.html) 42. November 3, 2022: [Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022: Recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults](https://web.archive.org/web/20221103170042/https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/summary-national-advisory-committee-immunization-november-3-2022-recommendations-use-moderna-spikevax-bivalent-mrna-50-mcg-covid-19-booster-vaccine-adults.html) 43. December 9, 2022: [Updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration](https://web.archive.org/web/20230120175642/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/updated-recommendations-use-covid-19-vaccine-booster-doses-children-5-11-years-concurrent-administration.html) - [Summary of NACI statement of December 9, 2022: Updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration](https://web.archive.org/web/20230127090847/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/updated-recommendations-use-covid-19-vaccine-booster-doses-children-5-11-years-concurrent-administration/summary-december-9-2022.html) 44. January 20, 2023: [Guidance on COVID-19 vaccine booster doses: Initial considerations for 2023](https://web.archive.org/web/20230210071057/http://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-covid-19-vaccine-booster-doses-initial-considerations-2023.html) - [Summary of NACI statement of January 20, 2023: Guidance on COVID-19 vaccine booster doses: Initial considerations for 2023](https://web.archive.org/web/20230222082129/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-covid-19-vaccine-booster-doses-initial-considerations-2023/summary-january-20-2023.html) 45. March 3, 2023: [Guidance on an additional COVID-19 booster dose in the spring of 2023 for individuals at high risk of severe illness due to COVID-19](https://web.archive.org/web/20230314224140/https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-guidance-additional-covid-19-booster-dose-spring-2023-individuals-high-risk-severe-illness-due-covid-19.html) - [Summary of NACI statement of March 3, 2023: Guidance on an additional COVID-19 booster dose in the spring of 2023 for individuals at high risk of severe illness due to COVID-19](https://web.archive.org/web/20230314170045/https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-guidance-additional-covid-19-booster-dose-spring-2023-individuals-high-risk-severe-illness-due-covid-19-march-3-2023.html) 46. June 9, 2023: [Interim guidance on the use of bivalent Omicron-containing COVID-19 vaccines for primary series](https://web.archive.org/web/20230621103918/https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-interim-guidance-use-bivalent-omicron-containing-covid-19-vaccines-primary-series.html) - [Summary of NACI statement of June 9, 2023: Interim guidance on the use of bivalent Omicron-containing COVID-19 vaccines for primary series](https://web.archive.org/web/20230621103931/https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-interim-guidance-use-bivalent-omicron-containing-covid-19-vaccines-primary-series.html) 47. July 11, 2023: [Guidance on the use of COVID-19 vaccines in the fall of 2023](https://web.archive.org/web/20230720193257/https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/vaccines-immunization/national-advisory-committee-immunization-guidance-use-covid-19-vaccines-fall-2023/statement.pdf) - [Summary of National Advisory Committee on Immunization statement of July 11, 2023: Guidance on the use of COVID-19 vaccines in the fall of 2023](https://web.archive.org/web/20230810131158/https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-july-11-2023-guidance-use-covid-19-vaccines-fall.html) 48. September 12, 2023: [Addendum to the guidance on the use of COVID-19 vaccines in the fall of 2023](https://web.archive.org/web/20230921210834/https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-addendum-guidance-use-covid-19-vaccines-fall-2023.html) - [Summary supplemental statement: Addendum to the guidance on the use of COVID-19 vaccines in the fall](https://web.archive.org/web/20230930173504/https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-supplemental-statement-september-12-2023-addendum-guidance-use-covid-19-vaccines-fall.html) 49. October 27, 2023: [Updated guidance on the use of COVID-19 vaccines in individuals who have not previously been vaccinated against COVID-19](https://web.archive.org/web/20231208230619/https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-updated-guidance-covid-19-vaccines-individuals-not-previously-vaccinated.html) - [Summary of NACI statement of October 27, 2023: Updated guidance on the use of COVID-19 vaccines in individuals who have not previously been vaccinated against COVID-19](https://web.archive.org/web/20231203095102/https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-updated-guidance-covid-19-vaccines-individuals-not-previously-vaccinated.html) 50. January 12, 2024: [Guidance on an additional dose of COVID-19 vaccines in the spring for individuals at high risk of severe illness due to COVID-19](http://archive.today/2024.02.09-191036/https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-guidance-additional-dose-covid-19-vaccines-spring-2024-individuals-high-risk-severe-illness-due-covid-19.html) - [Summary of NACI statement of January 12, 2024: Guidance on an additional dose of COVID-19 vaccines in the spring of 2024 for individuals at high risk of severe illness due to COVID-19](http://archive.today/2024.02.09-190933/https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-guidance-additional-dose-covid-19-vaccines-spring-2024-individuals-high-risk-severe-illness-due-covid-19.html) ## External links - [Campfire Wiki](https://www.campfire.wiki/doku.php?id=national%5Fadvisory%5Fcommittee%5Fon%5Fimmunization) - [Wikipedia](https://en.wikipedia.org/wiki/National%5FAdvisory%5FCommittee%5Fon%5FImmunization) --- 1. Public Health Agency of Canada. (2022, September 16). *National Advisory Committee on Immunization (NACI): Terms of reference.* Government of Canada. [↩︎](#fnref1) 2. Public Health Agency of Canada. (2022, April 22). *National Advisory Committee on Immunization (NACI): Membership and representation.* Government of Canada. [↩︎](#fnref2) [↩︎](#fnref2:1) 3. Pelley, L. (2021, April 23). *Canadians over 30 should be offered AstraZeneca-Oxford COVID-19 vaccine, advisory body recommends.* CBC News. [↩︎](#fnref3) 4. Boynton, S. (2022, June 19). *COVID-19 boosters recommended this fall ahead of future pandemic wave: NACI.* Global News. [↩︎](#fnref4) 5. National Advisory Committee on Immunization. (2023, March 3). *Guidance on an additional COVID-19 booster dose in the spring of 2023 for individuals at high risk of severe illness due to COVID-19.* Public Health Agency of Canada. [↩︎](#fnref5) 6. Pelley, L. (2023, March 3). *COVID-19 booster shots recommended for high-risk Canadians starting this spring.* CBC News. [↩︎](#fnref6) 7. National Advisory Committee on Immunization. (2023, July 13). *Guidance on the use of COVID-19 vaccines in the fall: NACI, July 11, 2023.* Public Health Agency of Canada. [↩︎](#fnref7) 8. Ireland, N. (2023, July 11). *Get another COVID-19 booster in the fall, Canada’s immunization panel recommends.* CTV News. [↩︎](#fnref8) 9. Public Health Agency of Canada. (2022, April 22). *National Advisory Committee on Immunization (NACI): Membership and representation.* Government of Canada. [↩︎](#fnref9) 10. *National Advisory Committee on Immunization (NACI): Membership and representation.* (2020, December 18). Wayback Machine; Government of Canada. [↩︎](#fnref10) 11. Public Health Agency of Canada. (2024, January 12). *National Advisory Committee on Immunization (NACI): Statements and publications.* Government of Canada. [↩︎](#fnref11) ## Open Records Disclosures [Comparing US and Canadian COVID-19 vaccine recommendations in pregnancyQ-218![](https://storage.ghost.io/c/a2/fe/a2fe3cea-8d77-4702-87d4-ff1fd8934d08/content/images/icon/White-Rose-Logo-Symbol--favicon--114.ico)White Rose IntelligenceLiam Sturgess![](https://storage.ghost.io/c/a2/fe/a2fe3cea-8d77-4702-87d4-ff1fd8934d08/content/images/thumbnail/Public-Health-Agency-of-Canada-Q-218--feature-.png)](https://www.whiteroseintelligence.com/comparing-us-and-canadian-covid-19-vaccine-recommendations-in-pregnancy/)